Merck & Co. Stock News

Even pros can't beat the market. Forecasts fail, fees pile up, and short-term thinking hurts returns. So I stick to quality dividend stocks. I found two high-conviction dividend stocks that the market is underpricing. Both offer strong income and long-term upside if my thesis plays out. They aren't perfect, but that's where the opportunity lies. I believe the market's pessimism is overdone, and...

The liberation day market selloff has been entirely recovered during the month of May. Since inception, my watchlist has a CAGR of 14.81%, performing in-line with SPY and VYM, while providing a superior dividend yield. The June 2025 watchlist includes 10 stocks with an average forward dividend yield of 3.62% and an expected return of 13.63%.

Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, according to results of a large trial presented on Saturday.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that KEYTRUDA® (pembrolizumab) plus Trodelvy® (sacituzumab govitecan-hziy) reduced the risk of disease progression or death by 35% (HR=0.65, p

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today safety and efficacy results from the open-label Phase 1 KANDLELIT-001 study, a clinical trial evaluating MK-1084, an investigational next-generation KRAS G12C inhibitor, alone and in combination with other therapies in certain patients with KRAS G12C-mutant solid...

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Zilovertamab Vedotin Plus SOC Showed Promising Antitumor Activity, Complete Response Rate, in Relapsed/Refractory DLBCL in waveLINE-003 Trial.

Merck & Co., Inc. (NYSE:MRK ) Bernstein 41st Annual Strategic Decisions Conference May 29, 2025 3:30 PM ET Corporate Participants Rob Davis - Chairman and Chief Executive Officer Dean Li - Executive Vice President, President of Merck Research Labs Conference Call Participants Courtney Breen - Bernstein Courtney Breen All right. So, we might kick off our conversation with Merck today.

Merck and Japan-based Daiichi Sankyo said on Thursday they have withdrawn the U.S. application for an experimental lung cancer treatment, which belongs to a lucrative class of cancer therapies that work like "guided missiles".